Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice
David R. Martinez, Alexandra Schäfer, Sarah R. Leist, et al.
Science (2021) Vol. 373, Iss. 6558, pp. 991-998
Open Access | Times Cited: 177

Showing 76-100 of 177 citing articles:

Lineage-mosaic and mutation-patched spike proteins for broad-spectrum COVID-19 vaccine
Yangtao Wu, Shaojuan Wang, Yali Zhang, et al.
Cell Host & Microbe (2022) Vol. 30, Iss. 12, pp. 1732-1744.e7
Open Access | Times Cited: 21
Vaccine-mediated protection against Merbecovirus and Sarbecovirus challenge in mice
David R. Martinez, Alexandra Schäfer, Tyler D. Gavitt, et al.
Cell Reports (2023) Vol. 42, Iss. 10, pp. 113248-113248
Open Access | Times Cited: 11
Efficacy of the oral nucleoside prodrug GS-5245 (Obeldesivir) against SARS-CoV-2 and coronaviruses with pandemic potential
David R. Martinez, Fernando R. Moreira, Mark R. Zweigart, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 10
Hybrid immunity to SARS-CoV-2 arises from serological recall of IgG antibodies distinctly imprinted by infection or vaccination
William N. Voss, Michael Mallory, Patrick O. Byrne, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 3
Adjuvant-dependent impact of inactivated SARS-CoV-2 vaccines during heterologous infection by a SARS-related coronavirus
Jacob A. Dillard, Sharon Taft-Benz, Audrey C. Knight, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 3
Revisiting the dimensions of universal vaccine with special focus on COVID-19: Efficacy versus methods of designing
Puja Jaishwal, Kisalay Jha, Satarudra Prakash Singh
International Journal of Biological Macromolecules (2024) Vol. 277, pp. 134012-134012
Closed Access | Times Cited: 3
Multi-antigen intranasal vaccine protects against challenge with sarbecoviruses and prevents transmission in hamsters
Ankita Leekha, Arash Saeedi, K M Samiur Rahman Sefat, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 3
Beyond COVID-19: the promise of next-generation coronavirus vaccines
Reshma Koolaparambil Mukesh, Claude Kwe Yinda, Vincent J. Munster, et al.
npj Viruses (2024) Vol. 2, Iss. 1
Open Access | Times Cited: 3
Broad cross neutralizing antibodies against sarbecoviruses generated by SARS-CoV-2 infection and vaccination in humans
Yabin Hu, Qian Wu, Fangfang Chang, et al.
npj Vaccines (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 3
Structural basis for broad sarbecovirus neutralization by a human monoclonal antibody
M. Alejandra Tortorici, Nadine Czudnochowski, Tyler N. Starr, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 24
Protein engineering responses to the COVID-19 pandemic
Ching‐Lin Hsieh, Jason S. McLellan
Current Opinion in Structural Biology (2022) Vol. 74, pp. 102385-102385
Open Access | Times Cited: 18
Rational design of an influenza-COVID-19 chimeric protective vaccine with HA-stalk and S-RBD
Yulei Li, Peipei Liu, Tianjiao Hao, et al.
Emerging Microbes & Infections (2023) Vol. 12, Iss. 2
Open Access | Times Cited: 9
Impact of stabilizing mutations on the antigenic profile and glycosylation of membrane-expressed HIV-1 envelope glycoprotein
Tommy Tong, Alessio D’Addabbo, Jiamin Xu, et al.
PLoS Pathogens (2023) Vol. 19, Iss. 8, pp. e1011452-e1011452
Open Access | Times Cited: 9
Medium-term scenarios of COVID-19 as a function of immune uncertainties and chronic disease
Chadi M. Saad-Roy, Sinead E. Morris, Rachel E. Baker, et al.
Journal of The Royal Society Interface (2023) Vol. 20, Iss. 205
Open Access | Times Cited: 9
The shifting sands of ‘gain-of-function’ research
Amber Dance
Nature (2021) Vol. 598, Iss. 7882, pp. 554-557
Open Access | Times Cited: 20
Multiplexed LNP-mRNA vaccination against pathogenic coronavirus species
Lei Peng, Zhenhao Fang, Paul Renauer, et al.
Cell Reports (2022) Vol. 40, Iss. 5, pp. 111160-111160
Open Access | Times Cited: 15
Vaccines against SARS-CoV-2 variants and future pandemics
Taeyoung Park, Hyogyeong Hwang, Suhyeong Moon, et al.
Expert Review of Vaccines (2022) Vol. 21, Iss. 10, pp. 1363-1376
Open Access | Times Cited: 15
A potent, broadly protective vaccine against SARS-CoV-2 variants of concern
Ziyan Wang, Jiao An, Kunpeng Liu, et al.
npj Vaccines (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 14
Harnessing synthetic biology for advancing RNA therapeutics and vaccine design
Blaine A. Pfeifer, Marie Beitelshees, Andrew Hill, et al.
npj Systems Biology and Applications (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 8
Emergence of SARS and COVID-19 and preparedness for the next emerging disease X
Ben Hu, Hua Guo, Hao-Rui Si, et al.
Frontiers of Medicine (2024) Vol. 18, Iss. 1, pp. 1-18
Closed Access | Times Cited: 2
The small molecule inhibitor of SARS-CoV-2 3CLpro EDP-235 prevents viral replication and transmission in vivo
Michael H. J. Rhodin, Archie C. Reyes, Anand Balakrishnan, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 2
Distinct sensitivities to SARS-CoV-2 variants in vaccinated humans and mice
Alexandra C. Walls, Laura A. VanBlargan, Kaichun Wu, et al.
Cell Reports (2022) Vol. 40, Iss. 9, pp. 111299-111299
Open Access | Times Cited: 13
Computational design of a neutralizing antibody with picomolar binding affinity for all concerning SARS-CoV-2 variants
Bo-Seong Jeong, Jeong Ho Seok, Insu Hwang, et al.
mAbs (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 12
A pan-variant mRNA-LNP T cell vaccine protects HLA transgenic mice from mortality after infection with SARS-CoV-2 Beta
Brandon Carter, Pinghan Huang, Ge Liu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 7
Advances of Nanotechnology Toward Vaccine Development Against Animal Infectious Diseases
Xinlian Wang, Xinglong Gao, Liuxiang Wang, et al.
Advanced Functional Materials (2023) Vol. 33, Iss. 46
Open Access | Times Cited: 7

Scroll to top